Mizuno Toshiki, Kondo Masaki, Ishigami Noriko, Tamura Aiko, Itsukage Masahiro, Koizumi Hideyuki, Isayama Reina, Hosomi Akiko, Nagakane Yoshinari, Tokuda Takahiko, Sugimoto Eizo, Ushijima Yo, Nakagawa Masanori
Department of Molecular Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Clin Neuropharmacol. 2009 Mar-Apr;32(2):113-6. doi: 10.1097/WNF.0b013e31816c82a6.
A 64-year-old woman was admitted to our hospital for recurrent stroke and cognitive impairment and was diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Iodine-123 iodoamphetamine single photon emission computed tomography showed hypoperfusion in the whole brain, but cerebral blood flow increased dramatically after the administration of acetazolamide in the cerebral cortex. Lomerizine, a diphenylmethylpiperazine Ca2+ channel blocker, can selectively increase cerebral blood flow. Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients.
一名64岁女性因复发性中风和认知障碍入住我院，被诊断为伴有皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病（CADASIL）。碘-123 碘安非他明单光子发射计算机断层扫描显示全脑灌注不足，但在大脑皮质给予乙酰唑胺后脑血流量显著增加。洛美利嗪是一种二苯甲基哌嗪钙通道阻滞剂，可选择性增加脑血流量。在该CADASIL患者服用洛美利嗪2年期间，认知功能衰退和脑灌注不足有所改善，因此，洛美利嗪是治疗CADASIL患者认知障碍的潜在候选药物。
